JP2002501015A5 - - Google Patents

Download PDF

Info

Publication number
JP2002501015A5
JP2002501015A5 JP2000528271A JP2000528271A JP2002501015A5 JP 2002501015 A5 JP2002501015 A5 JP 2002501015A5 JP 2000528271 A JP2000528271 A JP 2000528271A JP 2000528271 A JP2000528271 A JP 2000528271A JP 2002501015 A5 JP2002501015 A5 JP 2002501015A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000528271A
Other languages
Japanese (ja)
Other versions
JP2002501015A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP1998/000345 external-priority patent/WO1999037289A1/en
Publication of JP2002501015A publication Critical patent/JP2002501015A/ja
Publication of JP2002501015A5 publication Critical patent/JP2002501015A5/ja
Pending legal-status Critical Current

Links

JP2000528271A 1998-01-22 1998-01-22 リーシュマニア症の治療における経口投与のためのミルテフォシンを含有する固形医薬品 Pending JP2002501015A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1998/000345 WO1999037289A1 (en) 1998-01-22 1998-01-22 Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis

Publications (2)

Publication Number Publication Date
JP2002501015A JP2002501015A (ja) 2002-01-15
JP2002501015A5 true JP2002501015A5 (enExample) 2005-12-22

Family

ID=8166843

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000528271A Pending JP2002501015A (ja) 1998-01-22 1998-01-22 リーシュマニア症の治療における経口投与のためのミルテフォシンを含有する固形医薬品

Country Status (24)

Country Link
US (1) US6544551B1 (enExample)
EP (1) EP1051159B1 (enExample)
JP (1) JP2002501015A (enExample)
KR (1) KR100517399B1 (enExample)
CN (1) CN100413492C (enExample)
AT (1) ATE215817T1 (enExample)
AU (1) AU756805B2 (enExample)
BR (1) BR9814772A (enExample)
CA (1) CA2318260C (enExample)
CZ (1) CZ299229B6 (enExample)
DE (1) DE69804865T2 (enExample)
DK (1) DK1051159T3 (enExample)
ES (1) ES2175663T3 (enExample)
HU (1) HUP0004363A3 (enExample)
IL (1) IL136196A (enExample)
NO (1) NO20003674D0 (enExample)
NZ (1) NZ505648A (enExample)
PL (1) PL189654B1 (enExample)
PT (1) PT1051159E (enExample)
SI (1) SI1051159T1 (enExample)
SK (1) SK284839B6 (enExample)
TR (1) TR200001717T2 (enExample)
UA (1) UA68372C2 (enExample)
WO (1) WO1999037289A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10203195A1 (de) * 2002-01-25 2003-08-07 Zentaris Ag Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen
US7887817B2 (en) * 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
BR0215680A (pt) * 2002-04-26 2005-02-01 Rudolf Perl Composição farmacêutica oral estável
WO2004012744A1 (de) 2002-07-30 2004-02-12 Zentaris Gmbh Anwendung von alkylphosphocholinen in kombination mit antitumormedikamenten
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
ATE380027T1 (de) 2003-09-09 2007-12-15 Fumapharm Ag Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma
DE14172396T1 (de) 2004-10-08 2015-01-08 Forward Pharma A/S Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester
US8703179B2 (en) 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
WO2010020276A1 (en) * 2008-08-19 2010-02-25 Orphanidis Pharma Research Gmbh Treatment of coccidian parasites
WO2011123691A1 (en) 2010-03-31 2011-10-06 Keryx Biopharmaceuticals, Inc. Perifosine and capecitabine as a combined treatment for cancer
US9358244B2 (en) 2010-11-22 2016-06-07 Oblita Therapeutics Bvba Solid dosage forms of oleyl phosphocholine
EP2723347B1 (en) 2011-06-24 2019-09-04 GRI Bio, Inc. Prevention and treatment of inflammatory conditions
EP2983709A1 (en) * 2013-04-08 2016-02-17 Academisch Medisch Centrum Miltefosin or perifosin for use in the treatment of ibd
JP6566450B2 (ja) 2014-09-17 2019-08-28 ステアライフ・インディア・プライベート・リミテッド 発泡組成物及びそれを製造する方法
CN104473941A (zh) * 2014-12-20 2015-04-01 长沙佰顺生物科技有限公司 一种含有米替福新的药物制剂及其制备方法
US11219594B2 (en) 2015-12-12 2022-01-11 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof
HRP20241585T1 (hr) 2019-04-12 2025-01-31 Oblita Therapeutics Bvba Fototaloženje metalnih oksida za elektrokromne uređaje

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE888444C (de) * 1951-11-10 1953-08-31 Benckiser Gmbh Joh A Verfahren zum Tablettieren von hygroskopischen Praeparaten
IE59778B1 (en) * 1985-12-04 1994-04-06 Max Planck Gesellschaft Medicament with anti-tumour action containing hexadecylphosphocholine
US4762658A (en) * 1986-10-08 1988-08-09 Central Soya Company, Inc. Method of tableting of de-oiled phosphatides (lecithin)
US5290769A (en) * 1989-09-27 1994-03-01 Asta Pharma Aktiengesellschaft Use of hexadecylphosphocholine for the treatment of psoriasis
EP0916343A1 (de) * 1989-09-27 1999-05-19 ASTA Medica Aktiengesellschaft Verwendung von Alkylphosphorsäure-Verbindungen zur Bekämpfung von Psoriasis-Erkrankungen
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis

Similar Documents

Publication Publication Date Title
BE2012C041I2 (enExample)
JP2002500080A5 (enExample)
JP2001518323A5 (enExample)
IN1999CH00212A (enExample)
BRPI9917862A2 (enExample)
JP2001523854A5 (enExample)
BRPI9914151B8 (enExample)
BE2011C024I2 (enExample)
JP2002501015A5 (enExample)
JP2001516837A5 (enExample)
BRPI9917863A2 (enExample)
JP2544563C (enExample)
JP2512641Z (enExample)
JP2513847C (enExample)
IN187162B (enExample)
JP2577658C (enExample)
JP2579658C (enExample)
JP2620353C (enExample)
IN189878B (enExample)
JP2621143C (enExample)
IN192830B (enExample)
CN3083527S (enExample)
CN3080620S (enExample)
CN3083603S (enExample)
CN3072760S (enExample)